Immunotherapy works by enhancing the immune system rather than directly attacking cancer cells. RGA’s clinical oncologist, Dr. Radi Counsell, discusses how modern approaches to immunotherapy are transforming cancer survival rates for individuals fighting aggressive cancers. In addition, Dr. Counsell will examine the underwriting and claims adjudication implications.
Concluding our 4-part 2022 interview series on cancer, Dr. Achim Regenauer answers questions for Life underwriters on cancer and genetics, questions relating both to cause and to advances in clinical medicine.
Multiparametric magnetic resonance imaging (mpMRI) is an imaging tool with growing use in diagnosis, risk assessment, and management of individuals with prostate cancer. Explore current challenges with prostate cancer detection and diagnosis, and the role of mpMRI.
In this third interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on advances in cancer therapy.
The global pandemic’s toll on cancer diagnoses and what it may mean for the future of US life expectancy
In this second interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on advances in cancer diagnostics.
In this first interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on general cancer trends, including trends relating to incidence, detection at earlier stages and overdiagnosis.
In this, the first of a 4-part series of insurance-focused articles on cancer, Dr. Achim Regenauer, Chief Medical Officer, focuses on how these advances translate into high-level trends, and why they are so important to Life & Health insurance – all in a concise bulleted format, so there’s no need to wade through complex medical descriptions or interpret sensationalized headlines.
Dr. Achim Regenauer shares an overview of this important study’s findings and his perspective on the impact on cancer detection and Life & Health insurance.
RGA’s consultant oncologist, Dr. Radi Counsell, discusses the ways liquid biopsies will change the face of cancer care, from screening and diagnosis to treatment monitoring and surveillance of survivors. Dr. Counsell also examines underwriting and claims adjudication implications of this emerging technology.